Guideline: Type 2 diabetes mellitus therapy: Metformin: A critical perspective;Norma terapêutica da diabetes mellitus tipo 2: Metformina uma perspectiva crítica

Acta Medica Portuguesa

Volumn 24, Issue 2, 2011, Pages 331-338

  Pinto, Daniel ^a   Heleno, Bruno ^a   Gallego, Rosa ^b   Santos, Isabel ^a   Santiago, Luiz Miguel ^c   Maria, Vasco ^d  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b Nucleo de Diabetes da Associacao Portuguesa de Medicos de Clinica Geral   (Portugal)

^c ACES Baixo Mondego I   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ARTICLE; DRUG CONTRAINDICATION; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PORTUGAL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PRACTICE GUIDELINES AS TOPIC;

EID: 79959964310     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. BOAVIDA JM, CARVALHO D, RAPOSO JF, SILVA PM, DUARTE R: Norma 001/2011 Terapêutica da Diabetes Mellitus tipo 2: metformina. Direcção-Geral da Saúde. Lisboa 07/01/2011
2. BOAVIDA JM, DUARTE A, VICENTE LF, RUAS MA, MELO PC: Norma 002/2011 Diagnóstico e Classificação da Diabetes Mellitus. Direcção-Geral da Saúde. Lisboa 14/01/2011
3. BOAVIDA JM, COSTA AL, CARVALHO R, OLIVEIRA R: Norma 005/2011 Diagnóstico Sistemático do Pé Diabético. Direcção-Geral da Saúde. Lisboa 21/01/2011
4. BOAVIDA JM, COSTA AL, CARVALHO R, OLIVEIRA R: Orientação 003/2011 Organização de cuidados, prevenção e tratamento do Pé Diabético. Direcção-Geral da Saúde. Lisboa 21/01/2011
5. BOAVIDA JM, CASTANHEIRA-DINIS A, TRAVASSOS A, CUNHA-VAZ J, GENRO V: Norma 006/2011 Diagnóstico Sistemático e Tratamento da Retinopatia Diabética. Direcção-Geral da Saúde. Lisboa 27/01/2011
6. SOUSA JC: Quantum Sufficit. Rev Port Clin Geral 2007;23:253-7
7. WOOLF SH, GROL R, HUTCHINSON A, ECCLES M, GRIMSHAW J: Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999;318(7182):527-530
8. GENUIS SJ: The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers? J Am Board Fam Pract 2005;18(5):419-425
9. GRILLI R, MAGRINI N, PENNA A, MURA G, LIBERATI A: Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000;355(9198):103-6
10. TRICOCI P, ALLEN JM, KRAMER JM, CALIFF RM, SMITH SC Jr: Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301(8):831-841
11. LEE DH, VIELEMEYER O: Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines. Arch Intern Med 2011;171(1):18-22
12. BROUWERS M, KHO ME, BROWMAN GP et al for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010;182(18):839-42
13. CABANA MD, RAND CS, POWE NR et al: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282(15):1458-65
14. FRANCKE AL, SMIT MC, DE VEER AJ, MISTIAEN P: Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 2008;8(1):38
15. AB E, DENIG P, VAN VLIET T, DEKKER JH. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract 2009;10(1):24
16. SAFFORD MM, SHEWCHUK R, QU H: Reasons for not intensifying medications: differentiating clinical inertia from appropriate care. J Gen Intern Med 2007;22(12):1648-55
17. LUGTENBERG M, ZEGERS-VAN SCHAICK JM, WESTERT GP, BURGERS JS: Why don't physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners. Implementation Sci 2009;4(1):54
18. UKPDS Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865
19. SAENZ A, FERNANDEZ-ESTEBAN I, MATAIX A, AUSEJO M, ROQUE M, MOHER D: Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(3):CD002966
20. SELVIN E, BOLEN S, YEH HC et al: Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168(19):2070-80
21. NATHAN DM, BUSE JB, DAVIDSON MB et al: [ADA EASD] American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
22. [NICE CG66] National Collaborating Centre for Chronic Conditions: Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal Coll Physic 2008
23. IDF Clinical Guidelines Task Force: Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation 2005
24. UK Prospective Diabetes Study (UKPDS) Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
25. HOLMAN RR, PAUL SK, BETHEL MA, MATTHEWS DR, NEIL HAW: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89
26. DORMANDY JA, CHARBONNEL B, ECKLAND DJA et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
27. RICHTER B, BANDEIRA-ECHTLER E, BERGERHOFF K, CLAR C, EBRAHIM SH: Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(4):CD006060
28. RICHTER B, BANDEIRA-ECHTLER E, BERGERHOFF K, LERCH CL: Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;(2):CD006739
29. Van de Laar FA, LUCASSEN PL, AKKERMANS RP et al: Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(2):CD003639
30. BLACK C, DONNELLY P, MCINTYRE L, ROYLE PL, SHEPHERD JP, THOMAS S: Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD004654
31. CURRIE CJ, PETERS JR, TYNAN A et al: Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-9
32. Glucophage 500 mg: Resumo das características do medicamento [Internet]. Infarmed. 25/08/2010. Disponível em: http:// www.infarmed.pt/infomed/download_ficheiro.php?med_id=3975&tipo_doc=rcm [acedido a 13/02/2011]
33. Glucophage - Label [Internet]: FDA. 27/08/2008. Disponível em: http://www.accessdata.fda.gov/ drugsatfdadocs/label/ 2008/020357s031,021202s016lbl.pdf [acedido a 13 de Fevereiro de 2011]
34. SALPETER SR, GREYBER E, PASTERNAK GA, SALPETER EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;(4):CD002967
35. MCCORMACK J, JOHNS K, TILDESLEY H: Metformin's contraindications should be contraindicated. CMAJ 2005; 173(5):502-4
36. TAHRANI AA, VARUGHESE GI, SCARPELLO JH, HANNA FW: Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007;335:508-12
37. PILMORE HL: Review: metformin: potential benefits and use in chronic kidney disease. Nephrology 2010;15(4):412-8
38. EURICH DT, MCALISTER FA, BLACKBURN DF et al: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497
39. HOLSTEIN A, STUMVOLL M: Contraindications can damage your health - is metformin a case in point? Diabetologia 2005;48(12):2454-9
40. FANTUS IG: Metformin's contraindications: needed for now. CMAJ 2005;173(5):505-7
41. COLAGIURI S, DICKENSON S, GIRGIS S, COLAGIUIRI R: National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Canberra: Diabetes Australia and the NHMRC 2009.
42. NATHAN DM, BUSE JB, DAVIDSON MB et al: American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
43. DUCKWORTH W, ABRAIRA C, MORITZ T et al: VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-139
44. ADVANCE Collaborative Group, PATEL A, MACMAHON S, CHALMERS J et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72
45. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358:2545-59
46. ISMAIL-BEIGI F, CRAVEN T, BANERJI MA et al: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. 2010;376:419-430
47. RYDEN L, STANDL E, BARTNIK M et al: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2006;28(1):88-136
48. American Diabetes Association: Standards of Medical Care in Diabetes-2011. Diabetes Care 2010 12;34(Suppl1):11-61
49. SKYLER JS, BERGENSTAL R, BONOW RO et al: Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;92-93